



POLY MEDICURE LIMITED

Regd. Office: First Floor, 12, Sant Nagar, East of Kailash, New Delhi - 110 065
AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2009

(Rs. In lacs)

Sr. no.	Particulars	Quarter Ended		Year ended		Consolidated	
		31st March		31st March		Year Ended	
		2009	2008	2009	2008	2009	2008
		(Audited)		(Audited)		(Audited)	
1	Gross Sales/Income from operations	3105.37	2370.77	11383.96	8991.06	11383.96	8991.06
	Less-Excise Duty	34.44	47.45	161.60	152.89	161.60	152.89
	(a) Net Sales/Income from operations	3070.92	2323.32	11222.35	8838.16	11222.35	8838.16
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	3070.92	2323.32	11222.35	8838.16	11222.35	8838.16
2	Expenditure						
	a. (Increase)/Decrease in stock in trade and work in progress	156.47	(50.62)	(48.91)	(91.61)	(48.91)	(91.61)
	b. Consumption of Raw materials	1076.81	1016.08	4419.62	3975.78	4419.62	3975.78
	c. Purchase of traded goods	44.39	39.70	137.91	63.49	137.91	63.49
	d. Employee Cost	369.36	407.88	1644.34	1531.25	1644.34	1531.25
	e. Depreciation	143.72	165.50	646.40	555.93	671.76	572.33
	f. Other Expenditure	977.83	601.75	3343.86	2201.62	3348.96	2214.52
	g. total	2768.58	2180.31	10143.23	8236.46	10173.68	8265.76
3	Profit from Operations before Other Income, Interest & Exceptional items	302.34	143.01	1079.12	601.70	1048.67	572.40
4	Other Income	45.41	106.38	62.01	607.40	88.51	607.40
5	Profit before Interest & Exceptional items	347.75	249.40	1141.13	1209.10	1137.18	1179.80
6	Interest & Finance Charges	113.39	98.63	476.71	376.84	476.76	376.84
7	Profit after Interest but before Exceptional Items	234.36	150.77	664.43	832.26	660.42	802.96
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit/Loss from Ordinary activities before Tax	234.36	150.77	664.43	832.26	660.42	802.96
10	Tax Expenses						
	-Current Tax	26.55	17.09	75.28	94.30	75.28	94.30
	-Prior period tax	-22.04	0.00	(22.04)		(22.04)	0.00
	-Deferred Tax	60.48	1.34	85.92	32.59	85.92	32.59
	-Fringe Benefits Tax	-0.15	2.50	8.00	8.15	8.00	8.15
	-Credit for Minimum Alternative Tax (MAT)	(26.55)	(17.09)	(75.28)	(94.30)	(75.28)	(94.30)
11	Net Profit/Loss from Ordinary Activities after Tax	196.06	146.92	592.54	791.52	588.53	762.22
12	Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
	Add Loss attributable to minority interest					7.63	7.33
13	Net Profit/Loss for the period	196.06	146.92	592.54	791.52	596.16	769.55
14	Paid up Equity Share Capital (Face value Rs. 10/- per Share)	550.63	550.63	550.63	550.63	550.63	550.63
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year			4088.39	3647.33	4091.99	3625.35
16	Earning Per Share-Basic (Rs.)	3.56	2.74	10.76	14.54	10.83	14.00
	Earning Per Share-Diluted (Rs.)	3.56	2.59	10.76	13.73	10.83	13.22
17	Public shareholding						
	-No. of Shares	2853894	2891104	2853894	2891104	2853894	2891104
	-Percentage of Shareholding	51.83%	52.51%	51.83%	52.51%	51.83%	52.51%
18	Promoters and promoters group shareholding						
	a) Pledged / Encumbered						
	- Number of shares	0	0	0	0		
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)						
	- Percentage of shares (as a % of the total share capital of the Company)						
	b) Non-encumbered						
	- Number of shares	2652356	2615146	2652356	2615146		
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%		
	- Percentage of shares (as a % of the total share capital of the Company)	48.17%	47.49%	48.17%	47.49%		

- Notes:**
- The Company is primarily engaged in a business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
 - a. Other expenditure includes Exchange fluctuation loss of Rs. 313.43 Lacs for the quarter and Rs. 973.82 Lacs up to the quarter. (Exchange fluctuation gain of Rs. 97.65 Lacs for the quarter and Rs. 592.37 Lacs up to the quarter for the previous financial year is included in other Income).
 b. The Company has opted for accounting the exchange difference of long term foreign currency monetary items in line with Companies (Accounting Standards) amendment Rules 2009 with AS-11 notified by Government of India on 31st March 2009. Accordingly, the effect of exchange difference on long term foreign currency monetary items of the Company related to the acquisition of depreciable capital assets is adjusted to the cost of the assets amounting to Rs. 29.86 lacs and as a result, depreciation for the year is higher by 3.09 lacs. In other cases, same are accumulated in a Foreign Currency Monetary Translation Difference Account amounting to Rs. (-) 24.23 lacs to be amortised in the next two years.
 - The Board of Directors have recommended a dividend of Rs. 2.50 per equity share (previous year Rs. 2.50 per equity share) of Rs. 10 each, subject to approval of shareholders..
 - The Company received one investor complaint during the quarter, which was resolved. There was no pending complaint either at the beginning or end of the quarter.
 - The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 30th May,2009.
 - The figures for the corresponding periods have been restated, wherever necessary, to make them comparable.

By order of the Board

Place : New Delhi
 Date : 30.05.2009

Himanshu Baid
 Managing Director